

Sonoma Pharmaceuticals launches new UTI product in Australia and New Zealand

31 March 2022 | News

Sonoma Pharmaceuticals launches new Urinary Tract Infection(UTI) product through distributors in New Zealand, Australia and South Africa



US-based Sonoma Pharmaceuticals, a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia and South Africa.

Microdox is a super-oxidized solution based on Sonoma's patented Microcyn Technology intended to treat and prevent infections in the urinary tract and bladder. Microdox is a non-irritating and non-toxic solution and is ready for immediate use. Microdox is currently available through Sonoma's partners, Te Arai BioFarma in New Zealand and Australia, and NuAngle in South Africa.

"We believe Microdox is a unique bladder irrigation that fulfils the requirements of an effective adjunct UTI prevention and treatment for the removal of UTI-causing bacteria, bacterial biofilms and drug-resistant strains," said Scott Lissington, COO of Te Arai BioFarma.